You are here

Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension

Last updated on November 13, 2019

FOR MORE INFORMATION
Study Location
Kitasato University Hospital
Sagamihara, Kanagawa, 252-0375 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
1-17 year
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects weighing ≥8 kg.

- Subjects who have symptomatic pulmonary arterial hypertension due to one of the
following conditions:

- Idiopathic pulmonary arterial hypertension; or

- Heritable pulmonary arterial hypertension; or

- Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary
shunts. If the defect(s) is repaired, the subject's condition should be stabilized
hemodynamically; or

- Pulmonary arterial hypertension associated with d-transposition of the great arteries
repaired within the first 30 days of life; or

- Pulmonary arterial hypertension in subjects who have undergone surgical repair of
other congenital heart lesions and the condition should be stabilized hemodynamically
and do not have clinically significant residual left-sided heart disease.

- Subjects with a mean pulmonary artery pressure ≥25 mmHg at rest, PCWP ≤15 mmHg, and
PVRI ≥3 Wood units x m2. If PCWP is not available, then mean LA pressure ≤15 mmHg or
LVEDP ≤15 mmHg in the absence of left atrial obstruction.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Left-sided heart disease.

- Subjects with Down syndrome.

- Subjects with Obstructive Sleep Apnea, regardless of treatment status.

- Pericardial constriction.

- Subjects with significant (2+ for regurgitation) valvular disease other than tricuspid
or pulmonary regurgitation.

- Acutely decompensated heart failure within previous 30 days from screening.

- Subjects who have had an atrial septostomy within previous 6 months of screening.

- Subjects with hemodynamic instability or hypo- or hypertension at screening.

- Subjects with a history of stroke, myocardial infarction or life threatening
arrhythmia within 6 months of screening.

- Subjects with moderate to severe restrictive pulmonary disease (Total Lung Capacity or
Forced Vital Capacity ?60% of normal) or history of severe lung disease.

- Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.

- Subjects with history of pulmonary embolism.

- Subjects with known hereditary degenerative retinal disorders (such as retinitis
pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).

- Subjects who are known to be HIV positive.

- Subjects with impairment of renal function (serum creatinine >2.5 × ULN) or hepatic
function (ALT and/or AST >3 × ULN; and/or bilirubin ?2 mg/dL). Hematological
abnormalities (e.g., severe anemia, Hgb

- Subjects with severe hepatic dysfunction (Child-Pugh classification C).

- Change in class of medication for CHF or PAH within the 10 days prior to qualifying
right heart catheterization.

- Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in
any form.

- Subjects taking chronic arginine supplementation.

- Subjects who have received parenteral inotropic medication or parenteral vasodilators
within 30 days of Day 1.

- Subjects who are receiving alpha-blockers, nicorandil, amiodarone or potent cytochrome
P450 3A4 inhibitors.

- Subjects receiving chronic treatment with off-label sildenafil within 30 days of Day 1
are excluded. Subjects receiving an endothelin antagonist?PED5 inhibitor or,
prostacyclin/prostacyclin analogue within 30 days of randomization are excluded except
for beraprost.

- Pregnant females; breastfeeding females; males and females of childbearing potential
not using highly effective contraception or not agreeing to continue highly effective
contraception for at least 28 days after last dose of investigational product.

- Current or past illicit drug use or alcoholism excepting if abstinence can be
documented for ?1 year.

- Participation in another clinical trial of an investigational drug or device
(including placebo) within 30 days of screening for entry into the present study.

- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.

NCT01642407
Pfizer
Completed
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT03364244
All Genders
0+
Years
Tokyo,
Descriptive Information
Brief Title  ICMJE Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Official Title  ICMJE A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension
Brief Summary

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy.

Sildenafil was approved by the European Commission for the treatment of PAH in pediatric patients in May 2011, making it the first agent to be approved for the treatment of children with PAH. The approval was based on the largest placebo-controlled study to be conducted in this population. The recommended dose in pediatric patients aged 1 year to 17 years old is 10 mg TID in patients ? 20 kg and 20 mg TID for patients > 20 kg. Higher doses are not recommended in pediatrics patients.

This study is an open-label, multi-center study to investigate safety, efficacy and pharmacokinetics of sildenafil citrate in Japanese pediatric patients with PAH.

Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Pulmonary Arterial Hypertension
  • Hypertension, Pulmonary
Intervention  ICMJE Drug: Sildenafil
Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ? 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
Study Arms  ICMJE Experimental: Sildenafil
Intervention: Drug: Sildenafil
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 3, 2017)
6
Original Estimated Enrollment  ICMJE
 (submitted: July 13, 2012)
10
Actual Study Completion Date  ICMJE March 12, 2018
Actual Primary Completion DateMay 20, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects weighing ?8 kg.
  • Subjects who have symptomatic pulmonary arterial hypertension due to one of the following conditions:
  • Idiopathic pulmonary arterial hypertension; or
  • Heritable pulmonary arterial hypertension; or
  • Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts. If the defect(s) is repaired, the subject's condition should be stabilized hemodynamically; or
  • Pulmonary arterial hypertension associated with d-transposition of the great arteries repaired within the first 30 days of life; or
  • Pulmonary arterial hypertension in subjects who have undergone surgical repair of other congenital heart lesions and the condition should be stabilized hemodynamically and do not have clinically significant residual left-sided heart disease.
  • Subjects with a mean pulmonary artery pressure ?25 mmHg at rest, PCWP ?15 mmHg, and PVRI ?3 Wood units x m2. If PCWP is not available, then mean LA pressure ?15 mmHg or LVEDP ?15 mmHg in the absence of left atrial obstruction.

Exclusion Criteria:

  • Left-sided heart disease.
  • Subjects with Down syndrome.
  • Subjects with Obstructive Sleep Apnea, regardless of treatment status.
  • Pericardial constriction.
  • Subjects with significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation.
  • Acutely decompensated heart failure within previous 30 days from screening.
  • Subjects who have had an atrial septostomy within previous 6 months of screening.
  • Subjects with hemodynamic instability or hypo- or hypertension at screening.
  • Subjects with a history of stroke, myocardial infarction or life threatening arrhythmia within 6 months of screening.
  • Subjects with moderate to severe restrictive pulmonary disease (Total Lung Capacity or Forced Vital Capacity ?60% of normal) or history of severe lung disease.
  • Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.
  • Subjects with history of pulmonary embolism.
  • Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
  • Subjects who are known to be HIV positive.
  • Subjects with impairment of renal function (serum creatinine >2.5 × ULN) or hepatic function (ALT and/or AST >3 × ULN; and/or bilirubin ?2 mg/dL). Hematological abnormalities (e.g., severe anemia, Hgb <10 g/dL, leukopenia, WBC <2500/µL).
  • Subjects with severe hepatic dysfunction (Child-Pugh classification C).
  • Change in class of medication for CHF or PAH within the 10 days prior to qualifying right heart catheterization.
  • Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in any form.
  • Subjects taking chronic arginine supplementation.
  • Subjects who have received parenteral inotropic medication or parenteral vasodilators within 30 days of Day 1.
  • Subjects who are receiving alpha-blockers, nicorandil, amiodarone or potent cytochrome P450 3A4 inhibitors.
  • Subjects receiving chronic treatment with off-label sildenafil within 30 days of Day 1 are excluded. Subjects receiving an endothelin antagonist?PED5 inhibitor or, prostacyclin/prostacyclin analogue within 30 days of randomization are excluded except for beraprost.
  • Pregnant females; breastfeeding females; males and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for at least 28 days after last dose of investigational product.
  • Current or past illicit drug use or alcoholism excepting if abstinence can be documented for ?1 year.
  • Participation in another clinical trial of an investigational drug or device (including placebo) within 30 days of screening for entry into the present study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 1 Year to 17 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01642407
Other Study ID Numbers  ICMJE A1481298
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateSeptember 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]com

Call Now